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Background: Eczema is a common chronic disease which has significant morbidity and costs for children and their families. Phase One (1993) 
of the International Study of Asthma and Allergies in Childhood (ISAAC) found a high prevalence of symptoms of eczema in New Zealand.
Objective: In Phase Three (2001-3) we aimed to answer these three questions: Is the prevalence of eczema changing over time?; Are 
there ethnic differences in prevalence?; and What are the risk factors for eczema?
Methods: Five New Zealand centres participated in ISAAC Phases One and Three using the same methodology. Questionnaires about 
ethnicity, symptoms of eczema and environmental factors were completed by parents of 6-7 year olds (children) and self-completed by 
13-14 year olds (adolescents). Prevalence and change per year were calculated by centre, ethnicity and gender. Prevalence differences 
between centres and associations with environmental factors were examined using logistic regression.
Results: There was little change in prevalence over time for the children, and a decrease in prevalence for the adolescents. Prevalence 
was higher among Māori and even higher among Pacific participants than among European children. Positive associations with current 
eczema symptoms were found for both age groups for truck traffic in the street of residence, and current paracetamol consumption, 
and for children only, antibiotics or paracetamol in the 1st year of life. Inverse associations were found with residence in New Zealand 
less than 5 years, consumption of milk, seafood, and eggs, and presence of a dog in the home.
Conclusion: Eczema remains a significant problem, particularly for young Māori and Pacific New Zealanders in whom less recognition 
of eczema and poorer access to effective, sustained eczema management may be contributing factors. Reverse causation may explain 
all the environmental findings apart from truck traffic which is increasing in New Zealand.
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INTRODUCTION
Eczema is a common chronic disease which has significant 
morbidity and costs for children and their families. It is a common 
skin disease characterised by an itchy rash, often located in the 
flexural areas (e.g. folds of the elbows and knees), which frequently 
first occurs at a young age (less than 2 years) and follows a 
chronic relapsing course [1-3]. While many children with eczema 
experience remission as they grow up, approximately 20-40% 
of those affected will continue to experience eczema as adults 
[4, 5]. The high direct and indirect costs of chronic eczema to 
families and health care systems [6], and significant morbidity 
and impairment to quality of life in individuals [7] have been 
documented.
Concern that the prevalence of childhood eczema (as well as 
the prevalence of asthma and rhinitis) was increasing in affluent 
countries led to the establishment of the International Study of 
Asthma and Allergies in Childhood (ISAAC) in 1991 [8]. ISAAC used 
standardised methods to measure the prevalence of symptoms 
of asthma, rhinitis and eczema among children and adolescents 
in order to allow valid comparisons between centres, both within 
and between countries [9]. Six New Zealand centres (Auckland, 
Bay of Plenty, Hawke’s Bay, Wellington, Nelson and Christchurch, 
all in 1993) participated in ISAAC Phase One [10] with prevalence 
of current symptoms of eczema ranging from 12.0% to 16.6% 
and 12.1% to 13.8% for the 6-7 year and 13-14 year age groups 
respectively [11]. In ISAAC Phase Two, of the New Zealand centres, 
only Hawke’s Bay participated and the prevalence of current 
symptoms of flexural eczema was 14% detected by questionnaire 
and 8.2% detected by skin examination [12].
In 2002-3 ISAAC Phase Three took place, including five centres 
in New Zealand, repeating the methodology of Phase One [13] 
so that time trends in prevalence of symptoms could be assessed 
[14]. Prevalence of symptoms of asthma in New Zealand has 
been shown in phases One and Three to vary by ethnicity with 
high prevalence among Māori children and adolescents [15, 16]. 
However little is known about variation in prevalence by ethnicity 
and time trends for symptoms of eczema in New Zealand. An 
environmental questionnaire was added with questions about a 
variety of potential protective and risk factors.
Our hypotheses were that the prevalence of eczema in New 
Zealand is increasing, that it is more common among Māori and 
Pacific than European children and adolescents, and that there are 
some avoidable risk factors. The research objective was to answer 
these three questions: is eczema prevalence changing over time?; 
are there ethnic differences in prevalence?; and what are the risk 
factors for eczema?
 
MATERIALS AND METHODS
ISAAC Phase One (1993) and Phase Three (2001-3) in New 
Zealand surveyed parents of 6-7 year old children and 13-
14 year old adolescents concerning symptoms of asthma, 
rhinoconjunctivitis and eczema (core questionnaire), and, in Phase 
Three, added questions about environmental factors which may 
be associated with these diseases. Detailed information concerning 
the Phase One and Phase Three study design and questionnaires 
has been reported previously [9, 13]. Ethics Committee approval 
was obtained for each centre and centres obtained their own 
funding.
The questionnaire included demographic information 
concerning the age, date of birth, gender and ethnicity of 
participants. The ethnicity question included options for 
‘European/Pakeha’, ‘Māori’, ‘Pacific Island’ and ‘Other’ ethnicities 
and multiple selections were accepted. In cases where multiple 
options were selected a single ethnicity was allocated using a 
prioritisation of ‘Māori’, ‘Pacific Island’, ‘Other’ and ‘European/
Pakeha’ as for Phase One [15].
Schools were selected randomly from a defined sampling 
frame (except for Nelson where all schools in the study area 
participated). An information letter about the study was provided 
to parent/guardians of all eligible children. The questionnaires 
were completed at home by the parent/guardian of children, and 
self-completed by the adolescents at school. Passive consent was 
implied by return of the completed questionnaire to school by 
the children or failure to object to participation of the adolescents. 
Passive consent is associated with increased response rates and 
is acceptable for non-invasive questionnaire-based research in 
community settings [17].
The questions used in the ISAAC core questionnaire concerning 
symptoms of eczema were:
1.   Has your child/Have you ever had an itchy rash which was 
coming and going for at least six months? (Yes/No)
2.  Has your child/Have you had this itchy rash at any time in the 
past 12 months? (Yes/No)
3.   Has this itchy rash at any time affected any of the following 
places: the folds of the elbows, behind the knees, in front of 
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the ankles, under the buttocks, or around the neck, ears or 
eyes? (Yes/No)
4.  At what age did this itchy rash first occur? (Under 2 years/Age 
2-4 years/Age 5 or more) [for the parents of the children only]
5.   Has this itchy rash cleared completely at any time during the 
past 12 months? (Yes/No)
6.   In the past 12 months, how often on average, has your child/
have you been kept awake at night by this itchy rash? (Never/
Less than one night per week/One or more nights per week)
7.  Has your child/Have you ever had eczema? (Yes/No)
The main outcome measures of interest reported here are 
current symptoms of eczema (those participants who answered 
‘Yes’ to questions 2 and 3), and current symptoms of severe 
eczema (those participants with current symptoms of eczema 
who also answered ‘One or more nights per week’ to question 6). 
Results are also presented for question 7 (‘eczema ever’) to provide 
information about use of the label ‘eczema’. Early onset eczema 
was defined as participants with current symptoms of eczema 
who also replied “Under 2 years” for question 4 above, used only 
for the 6-7 year age group.
The environmental questions concerned weight, height, a range 
of dietary factors, physical exercise, cooking and heating fuels in 
the home, paracetamol use, antibiotic use, number of siblings, 
birth in New Zealand, years lived in New Zealand, maternal 
education, truck traf fic in street of residence, birth weight, 
breastfeeding, exposure to pets and farm animals, and exposure 
to environmental tobacco smoke in the home. Several questions 
concerning early life exposures were omitted from the 13-14 year 
age group questionnaire as adolescents could not be expected to 
provide valid responses.
Confidence intervals for the prevalence estimates were adjusted 
for the cluster sampling methodology. Logistic regression was 
used to examine whether there was more variation in prevalence 
of current symptoms of eczema, current symptoms of severe 
eczema and ‘eczema ever’ between centres than would be 
expected by chance, adjusted for gender, age, ethnicity, school 
decile (a surrogate measure of socio-economic status), and the 
cluster sampling methodology. Odds ratios for associations 
between the main outcome measures and environmental factors 
were also estimated using logistic regression, adjusted for gender, 
ethnicity, school decile, and the cluster sampling methodology. All 
analyses were carried out using SAS version 9.2 (SAS Institute Inc., 
Cary, NC, USA).
RESULTS
ISAAC Phase Three data was collected in Auckland and 
Wellington in 2001, Bay of Plenty in 2002, and Nelson and 
Christchurch in 2003. Four centres had response rates for both age 
groups greater than 80%: 6-7 year age group total 10,873 children, 
mean response rate of 85.2%, 13-14 year age group total 13,317 
adolescents, mean response rate 89.2%. The response rate for the 
children in Wellington was low (47.2%) and data from this age 
group in Wellington was excluded from the analysis and the time 
trends analysis.
The Phase One and Phase Three results by centre, ethnicity and 
gender (including change per year) are presented in Table 1. The 
combined (all centres) prevalence of symptoms in children and 
adolescents respectively for current eczema was 15.0% and 8.8%; 
severe eczema 1.8% and 1.3%; ‘eczema ever’ 31.5% and 26.1%.
There was greater variation between centres than would 
be expected by chance for all outcomes for both age groups 
(p < 0.001) with the exception of current symptoms of severe 
eczema for the adolescents (p = 0.092). Auckland had the highest 
prevalence of severe eczema but lowest prevalence of ‘eczema 
ever’ in both age groups. Christchurch had the highest prevalence 
of current symptoms of eczema and ‘eczema ever’ in children. 
Wellington had the highest prevalence of current symptoms of 
eczema and ‘eczema ever’ in adolescents and Christchurch the 
lowest. Nelson had the lowest prevalence in children of current 
symptoms of eczema and severe eczema and in adolescents of 
severe eczema.
For the children, there was generally little change in prevalence 
by centre between Phase One and Phase Three for current 
symptoms of eczema and current symptoms of severe eczema but 
increases in prevalence for ‘eczema ever’ were observed across all 
centres for this age group. There was a different pattern for the 
adolescents, with decreases for current symptoms of eczema and, 
to a lesser extent, current symptoms of severe eczema, and little 
change in ‘eczema ever’.
European/Pakeha and other participants had consistently lower 
prevalence than Māori who were lower than Pacific participants 
in both phases for current symptoms of eczema and current 
symptoms of severe eczema than, for Phase Three illustrated in 
Fig. 1. In contrast, for ‘eczema ever’, the pattern was reversed, 
with highest prevalence values found in European/Pakeha and 
Māori participants and lower values found for Pacific and other 
participants. There was no difference from the whole group in the 
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    Table 1. Phase One and Three prevalence, and change per year from Phase One (95% confidence intervals) by centre, ethnicity and gender for 
current symptoms of eczema, current symptoms of severe eczema and eczema ever
N N Current symptoms of eczema Current symptoms of severe eczema Eczema ever
Phase 
One
Phase 
Three
Phase 
One(%)
Phase 
Three(%)
Change Per 
Year*
(%)
Phase 
One(%)
Phase 
Three(%)
Change 
Per Year*
(%)
Phase 
One(%)
Phase 
Three(%)
Change Per 
Year*
(%)
6-7 year age group
Auckland 3,526 3,541 14.4 14.3 -0.00(-0.24,0.23) 2.6 2.5
-0.01
(-0.13,0.10) 22.3 26.4
0.45
(0.18,0.72)
Bay of Plenty 2,681 2,150 13.8 13.8 0.01(-0.23,0.24) 2.2 1.5
-0.07
(-0.16,0.02) 24.5 29.2
0.52
(0.23,0.82)
Nelson 1,868 1,867 12.0 11.6 -0.05(-0.28,0.19) 0.7 0.7
0.00
(-0.06,0.06) 24.4 32.5
0.82
(0.47,1.16)
Christchurch 3,318 3,315 15.8 18.5 0.27(0.07,0.47) 1.6 1.9
0.02
(-0.04,0.09) 28.8 37.9
0.91
(0.66,1.16)
Total for all centres 11,393 10,873 14.3 15.0 0.07(-0.04,0.18) 1.9 1.8
-0.01
(-0.06,0.04) 25.0 31.5
0.71
(0.54,0.88)
European/Pakeha 7,552 6,118 12.6 13.8 0.12(0.01,0.24) 0.9 0.8
-0.01
(-0.04,0.02) 26.5 34.3
0.78
(0.62,0.93)
Māori 2,245 2,578 17.9 17.2 -0.08(-0.32,0.16) 3.9 3.0
-0.10
(-0.21,0.02) 25.6 32.1
0.72
(0.44,1.01)
Pacific Island 891 818 20.4 20.8 0.04(-0.39,0.47) 4.9 5.4
0.05
(-0.19,0.29) 17.1 23.3
0.70
(0.27,1.12)
Other 624 1,307 12.8 13.1 0.03(-0.33,0.39) 2.7 2.1
-0.06
(-0.24,0.11) 17.0 22.0
0.55
(0.14,0.97)
Female 5,754 5,392 15.8 16.5 0.07(-0.08,0.23) 2.1 2.0
-0.01
(-0.07,0.05) 25.7 32.5
0.75
(0.57,0.94)
Male 5,639 5,481 12.6 13.6 0.11(-0.03,0.24) 1.7 1.6
-0.01
(-0.06,0.04) 24.3 30.5
0.68
(0.50,0.87)
13-14 year age group
Auckland 3,206 2,870 12.4   8.9 -0.43(-0.84,-0.03) 1.9 1.9
-0.00
(-0.13,0.12) 23.5 20.6
-0.37
(-0.80,0.06)
Bay of Plenty 2,813 1,976 13.8   8.1 -0.62(-1.01,-0.23) 2.4 1.0
-0.16
(-0.26,-0.07) 25.3 21.1
-0.48
(-1.11,0.16)
Wellington 4,417 3,050 13.2 12.1 -0.13(-0.41,0.14) 2.1 1.5
-0.06
(-0.14,0.01) 27.9 32.2
0.54
(0.03,1.06)
Nelson 1,838 2,305 12.8   7.5 -0.53(-0.83,-0.23) 1.5 0.7
-0.08
(-0.19,0.02) 26.2 26.8
0.05
(-0.49,0.60)
Christchurch 3,186 3,116 12.3   7.0 -0.52(-0.74,-0.31) 1.7 1.3
-0.04
(-0.11,0.02) 24.9 27.8
0.30
(-0.16,0.75)
Total for all centres 15,460 13,317 12.9   8.8 -0.49(-0.64,-0.34) 2.0 1.3
-0.08
(-0.12,-0.03) 25.7 26.1
0.03
(-0.23,0.29)
European/Pakeha 10,033 7,450 11.7   7.3 -0.43(-0.52,-0.35) 1.3 0.8
-0.05
(-0.08,-0.02) 27.4 28.8
0.14
(0.00,0.27)
Māori 2,937 2,501 16.9 10.4 -0.73(-0.93,-0.52) 3.7 2.1
-0.18
(-0.28,-0.08) 26.1 26.4
0.03
(-0.23,0.30)
Pacific Island 1,332 1,633 15.1 14.0 -0.13(-0.45,0.19) 3.5 2.8
-0.08
(-0.24,0.08) 18.2 22.5
0.54
(0.17,0.90)
Other 1,076 1,634 10.4   8.3 -0.27(-0.55,0.02) 1.4 1.0
-0.04
(-0.16,0.07) 17.8 17.4
-0.06
(-0.43,0.31)
Female 8,289 6,940 16.3 11.1 -0.52(-0.63,-0.41) 2.6 1.7
-0.09
(-0.14,-0.04) 31.5 31.6
0.02
(-0.13,0.16)
Male 7,171 6,372   9.0   6.4 -0.26(-0.35,-0.17) 1.3 1.0
-0.03
(-0.07,0.00) 19.0 20.1
0.10
(-0.03,0.24)
*Change per year values where the 95% confidence interval does not include 0% change per year are in bold type.
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pattern of change over time by ethnicity except for adolescents 
where decreases in prevalence for current symptoms of eczema 
and current symptoms of severe eczema were statistically 
significant only for European/Pakeha and Māori participants, and 
there were significant increases in prevalence of ‘eczema ever’ for 
European/Pakeha and Pacific participants.
All eczema symptoms were more common in girls than boys for 
both phases and both age groups. For the children, both genders 
showed a similar pattern of change between Phase Ones and 
Three as for the overall data. For the adolescents, the changes 
were similar for both genders for current symptoms of eczema 
(decrease) and current symptoms of severe eczema and ‘eczema 
ever’ showed little change.
Many environmental factors showed no association with 
eczema symptoms (Supplementary Tables 1 and 2). Positive 
associations (risk factors) with current symptoms of eczema, onset 
under 2 years, symptoms of severe eczema or ‘eczema ever’ were 
found for truck traffic in street of residence, current paracetamol 
use, paracetamol or antibiotic use in the first year of life. Inverse 
associations (potentially protective) were found for being resident 
in New Zealand fewer than 5 years, consumption of milk, and 
in the children only, current dog in the home, consumption of 
seafood, and eggs.
DISCUSSION
This study confirmed that eczema is common among children 
and adolescents in New Zealand. The prevalence of current 
eczema symptoms remains high, with New Zealand ranking 9th 
out of 60 countries among children and 39th among 96 countries 
among adolescents [18]. Current eczema symptoms are about 
twice as common in children (about 1 in 6) than in adolescents 
(about 1 in 12), although the difference in study methodology 
(parental report for the children vs. self-report for the adolescents) 
may be part of the explanation for this contrasting prevalence.
There was variation in prevalence between centres with 
inconsistent patterns except for Auckland which had the highest 
prevalence of current symptoms of severe eczema for both 
age groups but had the lowest prevalence of ‘eczema ever’ for 
both age groups. Nelson had the lowest prevalence of current 
symptoms of severe eczema for both age groups and also had a 
comparatively low prevalence of current symptoms of eczema 
in both age groups. Nelson had a lower prevalence of eczema 
in Phase One [11] and although various ideas for this lower 
prevalence have been put forward, there is no clear explanation.
Over the 9 year (average) time period somewhat different time 
trends were identified for the children (little change for current 
symptoms of eczema and severe eczema, and an increase for 
‘eczema ever’) and adolescents (decreases for current symptoms 
of eczema and severe eczema, and little change for ‘eczema ever’).
Prevalence of symptoms of eczema was highest among Māori 
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Fig. 1. (A) Eczema Prevalence in 6-7 yr age group in ISAAC Phase Three.
(B) Eczema Prevalence in 13-14 yr age group in ISAAC Phase Three.
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and Pacific participants for both phases. This contrasts with the 
Phase One asthma symptom results where European/Pakeha 
participants were intermediate between Māori and Pacific 
participants [15]. There was little evidence of changes in the 
burden of eczema symptoms between ethnic groups.
New Zealand children and adolescents have high rates of 
hospital admission for serious skin infection, which have been 
increasing over the last decade, have a clear social gradient and 
show marked ethnic gradients with Pacific 4.5 and Māori 2.8 
times the European rate [19]. Infected eczema makes a modest 
contribution to these figures, and points to under-treatment 
of eczema being a factor, as well managed eczema and early 
treatment of infected eczema would not normally be followed 
by hospital admission. Moreover Māori and Pacific children and 
adolescents are disproportionately affected by socioeconomic 
disadvantage (poverty) and thus the direct and indirect costs of 
doctors visits and treatments for eczema may be unsustainable for 
some families [20].
Prevalence of all  symptoms was higher among female 
participants which is consistent with many other studies [21]. 
Time trends in prevalence for both genders were generally similar, 
reflecting the overall patterns although there was an indication 
that the prevalence of severe symptoms decreased among females 
but not males in the adolescents.
Many potential aetiologic factors have been examined within 
New Zealand including antibiotics [22, 23], breastfeeding [23-
25], family history [23, 24, 26], maternal smoking [23], migration 
[27], immunisation [23, 28], paracetamol [22] and pets [23]. We 
found few consistent associations between eczema symptoms 
and reported environmental factors. Potential risk factors of 
particular interest were truck traffic in street of residence, current 
paracetamol use, paracetamol or antibiotic use in the first year of 
life. Those which showed potentially protective associations with 
current symptoms of eczema, onset under 2 years, symptoms 
of severe eczema or ‘eczema ever’, were being resident in New 
Zealand fewer than 5 years, consumption of milk, and in the 
children only, current dog in the home, consumption of seafood, 
and eggs. Reverse causation could be the explanations for many 
of these findings: paracetamol or antibiotics could be given for 
eczema, and consumption of milk, eggs, seafood, and exposure to 
dogs avoided because of eczema.
The associations with birth in New Zealand and years lived in 
New Zealand are consistent with data presented by Waite et al. 
[27] regarding eczema among Tokelauan children living in New 
Zealand and Tokelau, and a study of immigrant children in Italy 
which reported lower prevalence and incidence of eczema [29], 
and are consistent with the ISAAC findings for asthma [30].
The association with truck traffic is also consistent with the 
global level ISAAC Phase Three results [31]. Positive associations 
have also been reported among children in Germany [32] and 
Taiwan [33], and among adults in Sweden [34]. The findings are 
concerning because of the increase in truck traffic in New Zealand 
roads.
We examined early onset of eczema (less than 2 years of age) in 
the children because mutations in the filaggrin gene (an important 
structural protein in the epidermis) are strongly associated with 
the early eczema phenotype [35, 36]. The pattern of eczema 
prevalence and its association with environmental factors was 
similar for all current eczema symptoms and early onset of eczema 
symptoms, showing no distinguishing features for early onset of 
eczema symptoms.
The strengths of this study include par ticipation from 
centres from a number of regions within New Zealand and the 
standardised methodology, allowing valid comparisons between 
centres and ISAAC phases. The study was carried out to a high 
standard and achieved a high response rate. Rigorous data and 
methodology checks were used to reduce the risk of bias.
There are some limitations which should be acknowledged. 
Estimates of change per year in prevalence between Phase One 
and Phase Three have been presented in order to adjust for slightly 
different periods between phases among the participating centres. 
However, these values should not be interpreted as a consistent 
linear change. Recall bias may have affected the estimates of 
prevalence of ‘eczema ever’, and this may be worse for adolescents 
who may have difficulty accurately recalling early life events. For 
this study, eczema was defined by questionnaire, not examination 
by trained research staff. However an ISAAC Phase Two analysis 
comparing questionnaire and skin examination assessment of 
eczema has shown that the questionnaire is a valid measure in 
community-based studies [12]. The environmental questionnaire 
included a large number of questions (50 for the children and 38 
for the adolescents) and the questions were intentionally simple 
in order to be useable and translatable throughout the world. 
However some environmental factors which would have been of 
interest could not be included and it was not possible to examine 
any factor in depth.
Finally, this study has shown that young New Zealanders 
continue to experience a significant burden of eczema and this 
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burden is disproportionally higher among Māori and Pacific 
children and adolescents. It is vital that all New Zealand children 
and adolescents have timely, af fordable access to optimal 
management of eczema.
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  Supplementary Table 1.  Associations between EQ variables and current symptoms of eczema, current symptoms of severe eczema, eczema ever 
and early onset eczema, 6-7 year age group
Question Response category
Current symptoms 
of eczema
Current symptoms 
of severe eczema Eczema ever
Current symptoms 
of eczema and rash
 onset < 2 years
% Odds ratio*(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value*
Body mass 
 index
Normal 14.9 0.394 1.1 0.491 34.3    0.391 8.6 0.714
Overweight 15.7 1.05 (0.86,1.27) 1.7 1.39 (0.81,2.37) 32.5 0.93 (0.80,1.08) 8.3 0.96 (0.73,1.25)
Obese 13.1 0.86 (0.67,1.10) 1.6 1.04 (0.52,2.08) 30.2 0.90 (0.75,1.08) 7.3 0.88 (0.64,1.20)
Consumption 
 of meat
Never or occasionally 18.7 0.189 1.4 0.174 34.9    0.236 6.3 0.543
Once or twice per 
week
16.1 0.82 (0.60,1.13) 2.4 1.72 (0.64,4.61) 30.4 0.80 (0.62,1.03) 7.9 1.25 (0.79,1.97)
Three or more times a 
week
14.7 0.77 (0.56,1.05) 1.7 1.40 (0.49,4.03) 32.1 0.82 (0.65,1.05) 7.7 1.18 (0.75,1.85)
Consumption
 of seafood
Never or occasionally 15.9 0.094 1.8 0.157 34.7 <0.001 7.9 0.639
Once or twice per 
week
14.6 0.89 (0.80,0.99) 1.7 0.92 (0.67,1.26) 30.0 0.82 (0.75,0.90) 7.7 0.98 (0.85,1.12)
Three or more times a 
week
15.2 0.89 (0.64,1.22) 4.9 1.69 (0.91,3.16) 23.9 0.71 (0.53,0.95) 5.5 0.78 (0.45,1.33)
Consumption
 of fruit
Never or occasionally 15.6 0.738 1.2 0.556 35.8 0.114 6.2 0.676
Once or twice per week 15.7 0.97 (0.67,1.42) 2.6 1.79 (0.53,6.08) 28.8 0.75 (0.57,0.98) 7.2 1.22 (0.70,2.13)
Three or more times 
a week
15.0 0.92 (0.64,1.33) 1.8 1.52 (0.48,4.85) 32.0 0.80 (0.62,1.03) 7.8 1.25 (0.75,2.07)
Consumption 
 of vegetables
Never or occasionally 13.5 0.485 2.8 0.222 29.7    0.878 6.1 0.468
Once or twice per 
week
16.3 1.20 (0.89,1.63) 2.9 0.97 (0.55,1.71) 29.4 0.97 (0.77,1.23) 7.0 1.15 (0.73,1.80)
Three or more times a 
week
15.0 1.16 (0.89,1.52) 1.5 0.76 (0.45,1.30) 32.4 1.01 (0.83,1.22) 8.0 1.24 (0.82,1.87)
Consumption 
 of pulses
Never or occasionally 15.6 0.579 2.0 0.818 33.4    0.068 7.9 0.423
Once or twice per
week
14.7 0.95 (0.85,1.06) 1.7 1.00 (0.72,1.38) 31.3 0.91 (0.82,1.00) 7.9 1.00 (0.87,1.15)
Three or more times a 
week
15.3 1.01 (0.88,1.16) 1.6 0.89 (0.62,1.28) 30.9 0.89 (0.79,1.00) 7.0 0.89 (0.73,1.07)
Consumption 
 of cereal
Never or occasionally 16.9 0.173 3.1 0.053 20.8    0.028 4.6 0.672
Once or twice per week 17.4 1.02 (0.60,1.73) 3.9 1.32 (0.45,3.88) 24.8 1.17 (0.67,2.04) 6.7 1.39 (0.49,3.97)
Three or more times a 
week
14.9 0.86 (0.54,1.37) 1.7 0.75 (0.29,1.94) 32.4 1.43 (0.87,2.37) 7.8 1.46 (0.56,3.82)
Consumption 
 of pasta
Never or occasionally 16.0 0.653 2.9 0.442 25.9 <0.001 7.1 0.822
Once or twice per 
week
14.8 0.96 (0.85,1.10) 1.5 0.80 (0.57,1.13) 33.5 1.27 (1.13,1.42) 7.8 1.00 (0.83,1.20)
Three or more times a 
week
16.4 1.05 (0.87,1.26) 1.9 0.86 (0.53,1.41) 31.9 1.19 (1.01,1.40) 8.5 1.08 (0.81,1.45)
Consumption 
 of rice
Never or occasionally 14.2 0.438 1.8 0.479 32.7    0.017 7.7 0.895
Once or twice per 
week
15.2 1.06 (0.93,1.21) 1.5 0.87 (0.61,1.23) 33.6 1.03 (0.92,1.15) 8.0 1.02 (0.85,1.22)
Three or more times a 
week
16.0 1.13 (0.94,1.36) 2.9 1.03 (0.71,1.49) 24.5 0.84 (0.72,0.99) 6.9 1.07 (0.81,1.40)
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Consumption
 of butter
Never or occasionally 15.2    0.289 1.6 0.925 34.6 <0.001 8.6 0.023
Once or twice per week 15.9 1.04 (0.91,1.19) 1.8 0.93 (0.62,1.41) 30.2 0.86 (0.76,0.97) 7.7 0.92 (0.77,1.11)
Three or more times a 
week
14.8 0.93 (0.82,1.06) 2.1 1.01 (0.73,1.39) 29.8 0.83 (0.75,0.92) 6.8 0.80 (0.68,0.94)
Consumption
 of margarine
Never or occasionally 14.8    0.136 1.6 0.872 31.8    0.254 8.1 0.738
Once or twice per week 17.0 1.14 (0.96,1.35) 2.3 1.12 (0.69,1.81) 29.0 0.94 (0.80,1.10) 7.6 0.98 (0.77,1.24)
Three or more times a 
week
14.9 0.98 (0.86,1.10) 1.8 1.01 (0.73,1.39) 32.8 1.04 (0.94,1.15) 7.7 0.94 (0.80,1.10)
Consumption
 of nuts
Never or occasionally 15.7    0.185 1.9 0.458 33.8 <0.001 8.4 0.011
Once or twice per
 week
14.1 0.88 (0.76,1.01) 1.7 0.81 (0.56,1.16) 28.9 0.82 (0.75,0.91) 6.8 0.82 (0.69,0.98)
Three or more times a 
week
14.7 0.90 (0.67,1.21) 1.8 0.73 (0.33,1.60) 25.0 0.69 (0.55,0.88) 4.7 0.56 (0.35,0.89)
Consumption
 of potato
Never or occasionally 15.8    0.593 2.0 0.483 32.9    0.291 8.3 0.690
Once or twice per 
week
15.4 0.98 (0.76,1.25) 1.6 0.87 (0.46,1.66) 31.6 0.88 (0.73,1.06) 7.6 0.87 (0.62,1.22)
Three or more times a 
week
14.8 0.93 (0.73,1.19) 2.0 1.05 (0.54,2.02) 31.7 0.86 (0.70,1.04) 7.6 0.86 (0.61,1.21)
Consumption
 of milk
Never or occasionally 22.3 <0.001 3.5 0.009 43.3 <0.001 13.6 <0.001
Once or twice per 
week
16.5 0.66 (0.50,0.88) 2.2 0.53 (0.28,1.00) 30.5 0.58 (0.46,0.74) 7.5 0.51 (0.36,0.70)
Three or more times a 
week
14.5 0.57 (0.45,0.72) 1.7 0.43 (0.25,0.75) 31.2 0.58 (0.47,0.72) 7.4 0.49 (0.37,0.64)
Consumption
 of eggs
Never or occasionally 18.1 <0.001 2.0 0.238 38.3 <0.001 10.5 <0.001
Once or twice per 
week
14.5 0.75 (0.67,0.84) 1.6 0.72 (0.49,1.06) 31.7 0.76 (0.69,0.84) 7.5 0.69 (0.59,0.81)
Three or more times a 
week
13.2 0.64 (0.53,0.78) 2.4 0.74 (0.44,1.25) 22.3 0.53 (0.45,0.63) 4.4 0.42 (0.31,0.58)
Consumption
 of fast food
Never or occasionally 14.2    0.136 1.5 0.680 32.6    0.237 7.5 0.143
Once or twice per 
week
16.0 1.12 (1.00,1.25) 1.9 1.02 (0.76,1.37) 31.4 0.98 (0.90,1.07) 8.0 1.09 (0.94,1.25)
Three or more times a 
week
16.5 1.04 (0.75,1.43) 4.7 1.38 (0.67,2.87) 22.7 0.76 (0.55,1.05) 4.7 0.71 (0.44,1.12)
Frequency of
 exercise
Never or occasionally 17.1    0.172 3.9 0.007 25.4    0.012 6.8 0.841
Once or twice per 
week
15.5 0.92 (0.77,1.09) 1.5 0.56 (0.38,0.82) 31.7 1.17 (1.01,1.36) 7.9 1.04 (0.80,1.36)
Three or more times a 
week
14.3 0.85 (0.72,1.01) 1.5 0.63 (0.45,0.89) 33.2 1.20 (1.06,1.35) 7.8 0.99 (0.77,1.28)
Frequency 
 of television  
 viewing
Less than 1 hour 15.1    0.948 1.3 0.140 32.6    0.457 8.6 0.430
1 hour but less than 
3 hours
14.7 0.99 (0.86,1.14) 1.6 1.12 (0.72,1.75) 32.1 1.01 (0.91,1.13) 7.5 0.89 (0.75,1.05)
3 hours but less than 
5 hours
15.5 1.01 (0.83,1.24) 2.1 1.18 (0.71,1.98) 29.9 0.94 (0.82,1.07) 7.4 0.88 (0.71,1.09)
5 hours or more 15.7 1.03 (0.83,1.28) 3.5 1.89 (1.03,3.46) 30.4 0.98 (0.83,1.15) 6.7 0.80 (0.57,1.11)
Supplementary Table 1. (Cont’d)
Question Response category
Current symptoms 
of eczema
Current symptoms 
of severe eczema Eczema ever
Current symptoms 
of eczema and rash
 onset < 2 years
% Odds ratio*(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value*
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Cooking fuel Electricity only 14.9    0.583 1.8 0.313 31.1    0.350 7.6 0.817
Gas only 16.7 1.13 (0.96,1.34) 2.4 1.38 (0.89,2.12) 31.6 1.04 (0.91,1.19) 7.8 1.02 (0.79,1.32)
Fire/Wood only   9.5 0.60 (0.23,1.58) 33.3 1.07 (0.58,1.97) 7.1 0.91 (0.30,2.77)
Other fuel only 18.2 1.17 (0.23,5.94) 9.1 4.11 (0.50,34.08) 36.4 1.42 (0.37,5.38) 18.2 2.86 (0.53,15.51)
Multiple fuels 15.3 1.03 (0.84,1.27) 1.6 1.16 (0.64,2.10) 36.1 1.18 (1.01,1.38) 8.0 1.00 (0.76,1.31)
Heating fuel Electricity only 15.6    0.058 2.2    0.233 30.0                   
0.004
7.4    0.021
Gas only 13.2 0.83 (0.68,1.00) 1.4 0.68 (0.43,1.07) 29.7 0.90 (0.78,1.04) 6.0 0.74 (0.57,0.98)
Fire/Wood only 14.0 0.92 (0.78,1.08) 1.4 0.76 (0.51,1.15) 31.4 0.96 (0.86,1.08) 7.4 0.93 (0.75,1.16)
Other fuel only 16.9 1.06 (0.59,1.92) 2.8 1.29 (0.29,5.62) 32.4 1.06 (0.67,1.67) 8.5 1.09 (0.45,2.61)
Multiple fuels 16.6 1.09 (0.94,1.26) 1.8 1.04 (0.70,1.54) 35.7 1.15 (1.02,1.30) 9.4 1.17 (0.97,1.41)
Paracetamol
 use in the 1st
 year of life
No 10.1 0.8 21.2 4.4 <0.001
Yes 15.8 1.64 (1.35,2.00) 2.0 2.56 (1.41,4.64) 33.3 1.77 (1.56,2.01) 8.2 1.88 (1.49,2.37)
Current
 paracetamol
 use
Never 10.1 <0.001 0.9 <0.001 23.6 <0.001 5.6 <0.001
At least once a year 14.0 1.43 (1.14,1.78) 1.2 1.47 (0.67,3.26) 31.8 1.45 (1.24,1.70) 7.4 1.31 (0.97,1.76)
At least once a 
month
20.3 2.19 (1.72,2.79) 4.0 3.91 (1.82,8.42) 33.5 1.73 (1.45,2.05) 9.4 1.83 (1.30,2.57)
Antibiotic use
 in the 1st
 year of life
No 11.2 1.2 25.5 5.0 <0.001
Yes 17.5 1.69 (1.49,1.92) 2.2 1.86 (1.31,2.66) 35.5 1.59 (1.45,1.75) 9.4 1.99 (1.70,2.32)
Number of
 older siblings
0 siblings 15.1    0.859 1.4    0.209 34.1 <0.001 8.1    0.449
1 sibling 15.1 0.99 (0.88,1.12) 1.6 1.18 (0.84,1.66) 32.1 0.92 (0.84,1.01) 7.9 0.97 (0.83,1.14)
2 siblings 14.8 0.95 (0.81,1.10) 2.0 1.28 (0.80,2.04) 28.2 0.76 (0.67,0.87) 7.3 0.91 (0.75,1.10)
3 or more 
siblings
15.5 0.95 (0.79,1.14) 3.3 1.61 (1.03,2.50) 27.6 0.77 (0.67,0.88) 6.6 0.84 (0.66,1.06)
Number of
 younger
 siblings
0 siblings 15.4    0.418 1.7    0.732 31.0    0.345 7.5    0.882
1 sibling 14.4 0.91 (0.82,1.02) 1.6 0.89 (0.65,1.21) 32.6 1.07 (0.99,1.17) 7.8 1.04 (0.90,1.21)
2 siblings 15.8 0.98 (0.83,1.16) 2.4 1.12 (0.77,1.63) 32.3 1.08 (0.94,1.25) 8.0 1.08 (0.86,1.36)
3 or more 
siblings
16.1 0.91 (0.64,1.29) 3.0 0.98 (0.48,2.03) 29.4 1.02 (0.79,1.32) 7.6 1.09 (0.73,1.63)
Parity
 (version 1)
Not eldest 15.1    0.576 2.1 0.192 30.2 <0.001 7.5    0.034
Eldest 15.4 1.05 (0.95,1.17) 1.3 0.71 (0.48,1.03) 35.1 1.22 (1.12,1.33) 8.6 1.15 (1.00,1.31)
Only child 14.4 0.97 (0.80,1.18) 1.7 0.92 (0.56,1.49) 31.4 1.07 (0.92,1.26) 6.5 0.87 (0.66,1.14)
Parity
 (version 2)
Not eldest 15.1 2.1 30.2 7.5    0.322
Eldest 15.1 1.03 (0.93,1.14) 1.4 0.77 (0.56,1.05) 34.1 1.18 (1.09,1.28) 8.0 1.07 (0.94,1.22)
Birth in 
 New Zealand
No 10.7 1.6 19.3 3.4 <0.001
Yes 15.7 1.59 (1.29,1.96) 1.9 1.43 (0.83,2.47) 33.3 1.83 (1.52,2.19) 8.2 2.44 (1.63,3.64)
Years lived in
 New Zealand
6 years or more 15.7    0.002 1.9    0.638 33.2 <0.001 8.2    0.008
0-1 years 8.7 0.49 (0.33,0.73) 1.8 0.78 (0.29,2.14) 12.4 0.32 (0.23,0.43) 2.5 0.30 (0.14,0.64)
2-3 years 11.4 0.67 (0.47,0.96) 1.6 0.65 (0.25,1.69) 22.9 0.68 (0.51,0.91) 4.6 0.58 (0.33,1.01)
4-5 years 14.7 0.88 (0.72,1.07) 1.7 0.72 (0.41,1.27) 27.7 0.83 (0.69,1.00) 6.3 0.78 (0.56,1.07)
Supplementary Table 1. (Cont’d)
Question Response category
Current symptoms 
of eczema
Current symptoms 
of severe eczema Eczema ever
Current symptoms 
of eczema and rash
 onset < 2 years
% Odds ratio*(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value*
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Maternal
 education
Tertiary Institution 16.0 0.010 1.4 0.077 34.5 <0.001 8.9 0.001
No education 13.7 0.75 (0.52,1.10) 1.8 0.82 (0.36,1.84) 23.2 0.61 (0.45,0.82) 4.4 0.52 (0.29,0.93)
Primary school 16.9 0.99 (0.79,1.25) 3.8 1.75 (1.11,2.77) 28.3 0.83 (0.68,1.00) 7.4 0.88 (0.66,1.18)
Secondary school 14.1 0.85 (0.76,0.94) 2.0 1.21 (0.85,1.71) 29.7 0.82 (0.74,0.90) 6.7 0.76 (0.65,0.89)
Frequency of
 truck traffic
 in street of
 residence
Never 14.5 0.089 1.8 0.062 31.4    0.280 8.3 0.698
Seldom 15.1 1.04 (0.90,1.20) 1.6 0.80 (0.53,1.22) 32.7 1.10 (0.98,1.22) 7.5 0.90 (0.73,1.12)
Frequently through 
the day
14.5 0.98 (0.84,1.15) 1.8 0.82 (0.53,1.26) 30.7 1.04 (0.92,1.17) 7.8 0.98 (0.78,1.23)
Almost the whole 
day
18.7 1.29 (1.02,1.62) 4.1 1.49 (0.86,2.58) 28.0 0.99 (0.83,1.18) 6.9 0.89 (0.64,1.25)
Birth weight More than 4 kg 14.6 0.023 1.8 0.582 33.3    0.008 7.9 0.004
Less than 2.5 kg 14.1 0.95 (0.71,1.27) 1.9 0.94 (0.44,2.02) 28.0 0.80 (0.65,0.99) 6.0 0.74 (0.49,1.11)
2.5 - 3 kg 13.5 0.91 (0.73,1.13) 2.1 1.06 (0.59,1.93) 29.9 0.90 (0.77,1.05) 6.5 0.80 (0.61,1.05)
3 - 3.5 kg 14.7 0.99 (0.81,1.22) 1.4 0.72 (0.40,1.29) 31.9 0.95 (0.83,1.08) 7.4 0.91 (0.72,1.16)
3.5 - 4 kg 16.5 1.16 (0.96,1.41) 1.6 0.93 (0.58,1.48) 35.1 1.09 (0.96,1.24) 9.3 1.17 (0.91,1.51)
Breast fed No 14.0 2.6 28.0 6.3 0.047
Yes 15.3 1.12 (0.96,1.31) 1.6 0.71 (0.51,0.97) 32.4 1.17 (1.03,1.33) 8.0 1.24 (1.00,1.53)
Cat in the
 home in the 
 1st year of life
No 15.4 2.0 30.3 7.4 0.844
Yes 14.6 0.99 (0.88,1.11) 1.6 1.22 (0.89,1.67) 33.4 1.04 (0.95,1.13) 8.0 1.02 (0.87,1.18)
Current cat in
 the home
No 16.1 2.2 30.6 7.8 0.100
Yes 14.1 0.87 (0.78,0.98) 1.5 0.96 (0.70,1.31) 32.5 0.95 (0.87,1.04) 7.5 0.88 (0.75,1.03)
Dog in the 
home in the 
1st year of life
No 15.4 2.0 31.9 7.9 0.073
Yes 14.1 0.92 (0.81,1.05) 1.5 0.86 (0.59,1.23) 31.0 0.92 (0.84,1.02) 7.0 0.85 (0.72,1.01)
Current dog in 
the home
No 15.8 1.9 31.8 8.0 0.024
Yes 13.3 0.83 (0.73,0.94) 1.7 0.97 (0.72,1.32) 31.0 0.91 (0.83,1.00) 6.9 0.83 (0.70,0.98)
Exposure to 
animals in the 
1st year of life
No 15.3 1.8 32.2 7.8 0.072
Yes 13.4 0.88 (0.74,1.04) 2.0 1.14 (0.75,1.73) 26.5 0.75 (0.64,0.87) 6.3 0.80 (0.63,1.02)
Maternal
exposure to 
animals during 
pregnancy
No 15.2 1.8 32.0 7.7 0.468
Yes 14.0 0.94 (0.78,1.12) 1.8 1.07 (0.66,1.75) 28.6 0.84 (0.68,1.02) 7.0 0.91 (0.69,1.18)
Current 
maternal 
smoking
No 14.8 1.6 32.2 7.9 0.115
Yes 15.6 1.00 (0.88,1.13) 2.5 1.24 (0.90,1.72) 29.8 0.88 (0.80,0.98) 6.9 0.86 (0.71,1.04)
Number of 
cigarettes 
smoked by 
mother
No cigarettes 14.8 0.488 1.6 0.124 32.2    0.004 7.9 0.282
Less than 10 15.2 0.94 (0.76,1.16) 2.8 1.26 (0.80,1.99) 31.5 0.97 (0.84,1.13) 7.2 0.90 (0.70,1.17)
10 - 19 16.5 1.09 (0.93,1.27) 2.1 1.11 (0.73,1.70) 30.7 0.91 (0.80,1.04) 7.6 0.93 (0.73,1.17)
20 or more 13.6 0.89 (0.67,1.20) 3.6 1.95 (1.11,3.41) 24.2 0.66 (0.52,0.84) 5.1 0.64 (0.40,1.01)
Supplementary Table 1. (Cont’d)
Question Response category
Current symptoms 
of eczema
Current symptoms 
of severe eczema Eczema ever
Current symptoms 
of eczema and rash
 onset < 2 years
% Odds ratio*(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value* %
Odds ratio*
(95% CI)
p 
value*
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Current 
paternal 
smoking
No 14.6 1.6 32.1 7.6 0.376
Yes 16.2 1.10 (0.97,1.25) 2.2 1.00 (0.69,1.47) 30.5 0.98 (0.89,1.08) 7.9 1.09 (0.90,1.31)
Number of 
cigarettes 
smoked by 
father
No cigarettes 14.6 0.472 1.6 0.939 32.2 0.545 7.6 0.665
Less than 10 16.2 1.09 (0.89,1.35) 2.3 0.93 (0.52,1.67) 28.8 0.96 (0.81,1.14) 7.2 1.02 (0.74,1.42)
10 - 19 16.7 1.14 (0.96,1.35) 2.4 1.13 (0.67,1.91) 30.5 0.96 (0.83,1.11) 8.3 1.15 (0.90,1.47)
20 or more 14.7 1.00 (0.80,1.25) 2.1 1.06 (0.62,1.82) 28.9 0.89 (0.75,1.05) 7.0 0.95 (0.69,1.31)
Maternal 
smoking during 
1st year of life
No 14.9 1.6 32.2 7.9 0.153
Yes 15.5 1.00 (0.88,1.14) 2.5 1.24 (0.88,1.74) 29.8 0.87 (0.78,0.97) 7.1 0.86 (0.71,1.06)
Number of
 smokers in the
 home
No smokers 14.5 0.325 1.3 0.234 33.5 0.005 8.0 0.232
1 smoker 15.9 1.08 (0.95,1.22) 2.3 1.26 (0.88,1.82) 29.6 0.87 (0.79,0.97) 8.1 1.04 (0.86,1.26)
2 smokers 16.1 1.05 (0.88,1.26) 2.5 1.22 (0.79,1.86) 30.8 0.90 (0.78,1.04) 7.1 0.88 (0.67,1.15)
3 or more smokers 13.6 0.82 (0.57,1.17) 4.4 1.74 (0.98,3.09) 23.8 0.66 (0.51,0.86) 4.4 0.54 (0.29,1.03)
Parental
 smoking
Neither smokes 14.5 0.349 1.4 0.129 32.6 0.104 7.6 0.053
Father smokes 16.5 1.16 (0.99,1.37) 2.1 1.19 (0.74,1.90) 31.1 1.02 (0.89,1.16) 9.0 1.29 (1.03,1.61)
Mother smokes 15.1 1.02 (0.85,1.23) 2.8 1.63 (1.08,2.46) 29.7 0.87 (0.75,1.01) 7.1 0.94 (0.73,1.21)
Both smoke 15.8 1.04 (0.89,1.23) 2.2 1.12 (0.71,1.77) 29.9 0.89 (0.78,1.02) 6.7 0.88 (0.68,1.13)
* Statistically significant (at the 95% level) associations are identified by bold type.               
Supplementary Table 1. (Cont’d)
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Supplementary Table 2.  Associations between EQ variables and current symptoms of eczema, current symptoms of severe eczema and eczema 
ever, 13-14 year age group
Question Response category
Current symptoms of eczema Current symptoms of severe eczema Eczema ever
% Odds ratio*(95% CI)
p 
value*
p value* 
(overall) %
Odds 
ratio*
(95% CI)
p 
value*
p value* 
(overall) %
Odds ratio*
(95% CI)
p 
value*
p value* 
(overall)
Body mass 
 index
Normal   7.1 0.008 1.0 0.252 26.2    0.127
Overweight 10.2 1.44 
(1.14,1.82)
0.002 1.8 1.42 
(0.93,2.15)
0.104 23.3 0.95 
(0.82,1.10)
   0.484
Obese 10.9 1.47 
(1.04,2.09)
0.029 1.5 1.01 
(0.47,2.16)
0.981 25.7 1.19 
(0.92,1.53)
   0.183
Consumption
 of meat
Never or occasionally 10.1 0.016 1.2 0.852 27.8    0.011
Once or twice 
per week
  8.5 0.85 
(0.69,1.06)
0.146 1.4 1.14 
(0.50,2.57)
0.760 24.5 0.95 
(0.80,1.12)
   0.549
Three or more times 
a week
  9.1 0.98 (0.77,1.25) 0.858 1.3 1.19 
(0.55,2.59)
0.656 27.1 1.07 
(0.91,1.25)
   0.398
Consumption
 of seafood
Never or occasionally   8.5 0.078 1.3 0.085 28.2    0.010
Once or twice 
per week
  9.3 1.16 
(1.01,1.33)
0.035 1.1 0.87 
(0.65,1.15)
0.327 24.5 0.94 
(0.86,1.02)
   0.132
Three or more times 
a week
  9.4 1.10 
(0.84,1.43)
0.497 2.6 1.78 
(0.95,3.33)
0.073 17.6 0.69 
(0.52,0.91)
   0.008
Consumption
 of fruit
Never or occasionally 10.0 0.315 2.0 0.182 25.5    0.003
Once or twice 
per week
  8.4 0.76 
(0.53,1.08)
0.130 1.4 0.61 
(0.32,1.16)
0.133 23.5 0.88 
(0.71,1.09)
   0.243
Three or more times 
a week
  9.0 0.81 
(0.59,1.12)
0.209 1.3 0.57 
(0.31,1.04)
0.066 27.3 1.01 
(0.81,1.26)
   0.934
Consumption
 of vegetables
Never or occasionally 11.2 0.244 2.8 0.017 19.9    0.001
Once or twice 
per week
  8.6 0.78 
(0.58,1.05)
0.096 1.3 0.52 
(0.32,0.84)
0.008 23.6 1.21 
(0.94,1.57)
   0.135
Three or more times 
a week
  8.8 0.88 
(0.69,1.11)
0.277 1.2 0.58 
(0.39,0.88)
0.010 27.5 1.34 
(1.08,1.68)
   0.009
Consumption
 of pulses
Never or occasionally   8.9 0.003 1.6 0.004 25.1    0.081
Once or twice 
per week
  8.1 1.00 
(0.85,1.17)
0.998 1.0 0.70 
(0.47,1.04)
0.080 26.0 1.05 
(0.95,1.17)
   0.346
Three or more times 
a week
  9.8 1.26
(1.07,1.49)
0.005 1.5 1.17 
(0.79,1.72)
0.432 27.3 1.13 
(1.01,1.26)
   0.027
Consumption
 of cereal
Never or occasionally   9.3 0.595 1.5 0.798 23.7    0.159
Once or twice 
per week
  9.6 1.08 
(0.88,1.32)
0.484 1.5 1.04 
(0.53,2.04)
0.916 25.2 1.12 
(0.97,1.31)
   0.126
Three or more times 
a week
  8.6 1.02 
(0.82,1.27)
0.863 1.2 0.94 
(0.50,1.76)
0.842 26.8 1.18 
(1.00,1.39)
   0.055
Consumption
 of pasta
Never or occasionally   8.8 0.298 1.4 0.756 23.0    0.003
Once or twice 
per week
  8.8 1.10 
(0.96,1.26)
0.158 1.3 1.13 
(0.81,1.59)
0.464 27.6 1.17 
(1.07,1.28)
<0.001
Three or more times 
a week
  9.0 1.11 
(0.92,1.33)
0.263 1.3 1.13 
(0.70,1.82)
0.629 27.0 1.15 
(1.00,1.32)
   0.054
Consumption
 of rice
Never or occasionally   8.1 0.111 1.4 0.506 25.5 <0.001
Once or twice 
per week
  8.5 1.03 
(0.90,1.19)
0.661 1.2 0.80 
(0.54,1.19)
0.271 28.0 1.15 
(1.08,1.24)
<0.001
Three or more times 
a week
10.4 1.17 
(0.99,1.39)
0.058 1.6 0.89 
(0.55,1.42)
0.618 23.0 1.10 
(0.96,1.25)
   0.171
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Supplementary Table 2.  (Cont’d)
Question Response category
Current symptoms of eczema Current symptoms of severe eczema Eczema ever
% Odds ratio*(95% CI)
p 
value*
p value* 
(overall) %
Odds 
ratio*
(95% CI)
p 
value*
p value* 
(overall) %
Odds ratio*
(95% CI)
p 
value*
p value* 
(overall)
Consumption
 of butter
Never or occasionally   8.3    0.075 1.1 0.133 28.3 0.040
Once or twice 
per week
  8.3 0.96 
(0.82,1.14)
0.659 1.2 0.91 
(0.61,1.36)
0.641 24.7 0.90 
(0.82,0.98)
0.012
Three or more times 
a week
  9.9 1.18 
(0.99,1.41)
0.063 1.7 1.30 
(0.84,2.02)
0.239 25.6 0.96 
(0.87,1.06)
0.440
Consumption
 of margarine
Never or occasionally   8.5    0.645 1.4 0.376 26.4 0.044
Once or twice 
per week
  8.8 1.00 
(0.87,1.16)
0.960 1.4 0.87 
(0.54,1.41)
0.574 24.4 0.90 
(0.82,0.99)
0.035
Three or more times a 
week
  9.2 1.07 
(0.92,1.24)
0.382 1.2 0.75 
(0.50,1.14)
0.176 27.6 1.01 
(0.93,1.10)
0.817
Consumption
 of nuts
Never or occasionally   9.1    0.169 1.3 0.074 26.7 0.964
Once or twice 
per week
  8.3 0.97 
(0.85,1.10)
0.616 1.2 0.98 
(0.64,1.49)
0.920 25.8 1.01 
(0.93,1.09)
0.827
Three or more times 
a week
10.8 1.25 
(0.97,1.60)
0.082 2.5 1.80 
(1.03,3.12)
0.038 24.2 0.98 
(0.81,1.19)
0.863
Consumption of 
potato
Never or occasionally   9.6    0.683 2.3 0.061 22.6 0.651
Once or twice
 per week
  8.6 0.90 
(0.67,1.22)
0.504 1.1 0.49 
(0.27,0.89)
0.018 25.5 1.09 
(0.90,1.32)
0.396
Three or more times
 a week
  9.0 0.95 
(0.70,1.29)
0.733 1.4 0.61 
(0.37,1.01)
0.057 27.0 1.09 
(0.90,1.33)
0.358
Consumption of 
milk
Never or occasionally 10.9    0.327 2.3 0.023 28.6 0.209
Once or twice 
per week
  9.0 0.80 
(0.58,1.10)
0.172 1.1 0.43 
(0.24,0.79)
0.006 25.4 0.86 
(0.73,1.03)
0.097
Three or more times 
a week
  8.7 0.80 
(0.60,1.07)
0.137 1.3 0.56 
(0.31,0.99)
0.046 26.3 0.95 
(0.82,1.09)
0.460
Consumption 
 of eggs
Never or occasionally   8.4    0.617 1.2 0.885 27.6 0.244
Once or twice 
per week
  8.9 1.08 
(0.90,1.29)
0.430 1.3 1.08 
(0.78,1.50)
0.628 26.6 1.01 
(0.93,1.10)
0.731
Three or more times 
a week
  9.5 1.11 
(0.89,1.38)
0.358 1.5 1.09 
(0.72,1.67)
0.681 23.4 0.94 
(0.84,1.04)
0.224
Consumption
 of fast food
Never or occasionally   8.1    0.368 0.9 0.108 29.1 0.014
Once or twice 
per week
  8.9 1.04 
(0.91,1.19)
0.584 1.3 1.18 
(0.87,1.61)
0.288 25.4 0.90 
(0.82,0.99)
0.024
Three or more times 
a week
11.0 1.15 
(0.94,1.42)
0.182 2.2 1.49 
(1.03,2.16)
0.035 22.2 0.81 
(0.68,0.95)
0.012
Frequency
 of exercise
Never or occasionally   9.3    0.899 1.9 0.379 23.8 0.481
Once or twice
 per week
  9.1 1.03
(0.81,1.31)
0.836 1.2 0.74 
(0.44,1.26)
0.273 26.7 1.03 
(0.90,1.17)
0.693
Three or more times 
a week
  8.4 1.05 
(0.81,1.37)
0.701 1.3 0.90 
(0.47,1.73)
0.745 26.5 1.07 
(0.95,1.20)
0.290
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Supplementary Table 2.  (Cont’d)
Question Response category
Current symptoms of eczema Current symptoms of severe eczema Eczema ever
% Odds ratio*(95% CI)
p 
value*
p value* 
(overall) %
Odds 
ratio*
(95% CI)
p 
value*
p value* 
(overall) %
Odds ratio*
(95% CI)
p 
value*
p value* 
(overall)
Frequency 
of television 
viewing
Less than 1 hour   9.3    0.422 1.0 0.242 26.9 0.758
1 hour but less than 
3 hours
  8.2 0.88 
(0.72,1.06)
0.180 1.0 0.99 
(0.58,1.70)
0.964 26.3 0.95 
(0.80,1.13)
0.564
3 hours but less than 
5 hours
  8.9 0.95 
(0.77,1.16)
0.582 1.3 1.19 
(0.66,2.15)
0.560 26.3 0.99 
(0.86,1.15)
0.915
5 hours or more   9.7 0.98 
(0.77,1.25)
0.868 1.9 1.52 
(0.84,2.75)
0.171 25.2 1.01 
(0.86,1.18)
0.938
Cooking fuel Electricity only   8.7 <0.001 1.3 0.065 26.0 0.045
Gas only   7.2 0.83 
(0.68,1.03)
0.092 1.1 0.88 
(0.56,1.39)
0.586 25.6 1.00 
(0.89,1.13)
0.949
Fire/Wood only   9.5 1.00 
(0.42,2.42)
0.994 3.2 2.64 
(0.59,11.77)
0.204 15.9 0.62 
(0.30,1.28)
0.200
Other fuel only 13.3 1.62 
(0.52,5.06)
   0.405 3.3 2.20 
(0.27,18.14)
0.463 16.7 0.75 
(0.31,1.82)
   0.527
Multiple fuels 12.3 1.49 
(1.27,1.75)
<0.001 1.8 1.36 
(0.97,1.90)
0.077 28.9 1.18 
(1.04,1.33)
   0.008
Heating fuel Electricity only   8.2 <0.001 1.3 0.047 23.3 <0.001
Gas only   8.0 1.08 
(0.92,1.27)
   0.361 1.5 1.22 
(0.77,1.92)
0.400 25.9 1.11 
(0.99,1.26)
   0.080
Fire/Wood only   7.9 1.15 
(1.00,1.32)
   0.056 1.0 0.93 
(0.64,1.33)
0.675 25.6 1.10 
(1.00,1.21)
   0.057
Other fuel only 12.0 1.64 
(1.03,2.61)
   0.036 4.0 3.27 
(1.39,7.70)
0.007 22.7 0.99 
(0.67,1.45)
   0.962
Multiple fuels 10.9 1.55 
(1.32,1.81)
<0.001 1.3 1.15 
(0.81,1.63)
0.440 31.4 1.37 
(1.23,1.53)
<0.001
Current 
paracetamol 
use
Never   5.3 <0.001 1.3 0.007 18.4 <0.001
At least once a year   7.1 1.34 
(1.04,1.72)
   0.024 0.9 0.75 
(0.45,1.27)
0.285 23.2 1.21 
(1.04,1.40)
   0.016
At least once a month 11.1 2.05 
(1.61,2.61)
<0.001 1.6 1.25 
(0.83,1.88)
0.278 30.3 1.55 
(1.35,1.79)
<0.001
Number of 
older siblings
0 siblings   7.7    0.201 1.1 0.146 27.3    0.236
1 sibling   8.6 1.14 
(0.95,1.36)
   0.158 1.2 1.13 
(0.72,1.77)
0.603 26.8 0.97 
(0.86,1.09)
   0.587
2 siblings   9.0 1.16 
(0.93,1.46)
   0.189 1.0 0.89 
(0.47,1.68)
0.719 25.6 0.91 
(0.80,1.04)
   0.184
3 or more siblings 10.6 1.22 
(1.02,1.47)
   0.032 2.2 1.51 
(0.93,2.46)
0.094 23.7 0.86 
(0.74,1.00)
   0.049
Number of 
younger 
siblings
0 siblings   8.8    0.017 1.2 0.026 26.8    0.810
1 sibling   7.9 0.85 
(0.73,1.00)
   0.056 1.0 0.78 
(0.52,1.16)
0.222 26.4 0.98 
(0.89,1.08)
   0.654
2 siblings   8.8 0.90 
(0.74,1.09)
   0.291 1.1 0.73 
(0.42,1.27)
0.270 25.4 0.95 
(0.84,1.07)
   0.377
3 or more siblings 11.5 1.08 
(0.88,1.32)
   0.458 2.5 1.33 
(0.89,2.00)
0.163 24.9 0.95 
(0.83,1.09)
   0.491
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Supplementary Table 2.  (Cont’d)
Question Response category
Current symptoms of eczema Current symptoms of severe eczema Eczema ever
% Odds ratio*(95% CI)
p 
value*
p value* 
(overall) %
Odds 
ratio*
(95% CI)
p 
value*
p value* 
(overall) %
Odds ratio*
(95% CI)
p 
value*
p value* 
(overall)
Parity 
 (version 1)
Not eldest   9.2    0.027 1.4 0.638 25.6    0.263
Eldest   7.2 0.81
(0.67,0.98)
   0.031 1.0 0.86 
(0.58,1.27)
0.441 27.0 1.06 
(0.95,1.19)
   0.294
Only child 10.1 1.16 
(0.89,1.50)
   0.278 1.3 0.99 
(0.43,2.28)
0.973 28.4 1.16 
(0.96,1.41)
   0.123
Parity 
 (version 2)
Not eldest   9.2    0.081 1.4 0.536 25.6    0.188
Eldest   7.6 0.86 
(0.72,1.02)
   0.081 1.1 0.87 
(0.57,1.34)
0.536 27.2 1.08 
(0.97,1.20)
   0.188
Birth in New  
 Zealand
No   6.8 <0.001 1.3 0.904 15.7 <0.001
Yes   9.2 1.63 
(1.27,2.08)
<0.001 1.3 1.03 
(0.67,1.58)
0.904 28.3 1.91 
(1.57,2.32)
<0.001
Years lived in 
 New Zealand
9 years or more   9.2    0.003 1.3 0.432 28.1 <0.001
0-2 years   6.8 0.60 
(0.37,0.97)
   0.036 1.9 1.44 
(0.75,2.75)
0.271 13.0 0.45 
(0.35,0.57)
<0.001
3-5 years   6.3 0.57 
(0.38,0.85)
   0.007 1.1 0.80 
(0.38,1.67)
0.546 12.5 0.41 
(0.31,0.53)
<0.001
6-8 years   7.2 0.71 
(0.48,1.04)
   0.082 1.2 0.92 
(0.40,2.14)
0.847 18.9 0.66 
(0.53,0.82)
<0.001
Maternal 
 education
Tertiary Institution   8.0 0.218 1.3    0.044 24.8 <0.001
No education 10.7 1.19 
(0.96,1.47)
0.106 1.3 0.77 
(0.53,1.11)
   0.160 29.8 1.31 
(1.15,1.50)
<0.001
Primary school   9.8 1.05 
(0.68,1.61)
0.821 3.6 2.08 
(0.94,4.58)
   0.071 15.9 0.64 
(0.44,0.93)
   0.018
Secondary school   8.3 0.96 
(0.83,1.11)
0.606 1.3 0.84 
(0.63,1.12)
   0.236 25.3 1.03 
(0.95,1.11)
   0.485
Frequency of  
truck traffic 
in street of 
residence
Never   7.0 0.117 0.8    0.076 24.7    0.284
Seldom   8.5 1.15 
(0.93,1.42)
0.186 1.2 1.41 
(0.79,2.52)
   0.249 26.4 1.07 
(0.98,1.16)
   0.156
Frequently through 
the day
  9.8 1.26 
(0.98,1.61)
0.070 1.4 1.47 
(0.79,2.73)
   0.224 26.5 1.10 
(1.00,1.21)
   0.056
Almost the whole day 10.9 1.40 
(1.05,1.88)
0.021 2.4 2.35 
(1.22,4.51)
   0.010 25.4 1.09 
(0.93,1.26)
   0.293
Current cat in 
 the home
No   8.6 0.022 1.0 <0.001 23.6    0.072
Yes   9.0 1.20 
(1.03,1.39)
0.022 1.5 2.24 
(1.50,3.33)
<0.001 27.6 1.08 
(0.99,1.17)
   0.072
Current dog in 
 the home
No   8.8 0.478 1.4    0.853 25.6    0.906
Yes   8.9 1.05 
(0.92,1.20)
0.478 1.3 0.96 
(0.64,1.44)
   0.853 26.8 1.00 
(0.94,1.08)
   0.906
Current 
maternal 
smoking
No   8.3 0.078 1.1    0.017 26.3    0.547
Yes 10.2 1.13 
(0.99,1.28)
0.078 2.0 1.45 
(1.07,1.98)
   0.017 25.7 0.97 
(0.89,1.06)
   0.547
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Supplementary Table 2.  (Cont’d)
Question Response category
Current symptoms of eczema Current symptoms of severe eczema Eczema ever
% Odds ratio*(95% CI)
p 
value*
p value* 
(overall) %
Odds 
ratio*
(95% CI)
p 
value*
p value* 
(overall) %
Odds ratio*
(95% CI)
p 
value*
p value* 
(overall)
Number of 
 smokers in the 
 home
No smokers   7.6 0.122 0.9    0.046 26.6    0.015
1 smoker   9.2 1.12 
(0.94,1.32)
0.209 1.6 1.51 
(1.00,2.28)
   0.050 25.7 0.97 
(0.86,1.10)
   0.662
2 smokers 10.9 1.27 
(1.04,1.55)
0.019 2.2 1.80 
(1.19,2.72)
   0.006 27.7 1.09 
(0.96,1.23)
   0.190
3 or more smokers 11.3 1.20 
(0.92,1.56)
0.182 2.0 1.37 
(0.82,2.29)
   0.229 23.6 0.88 
(0.79,0.99)
   0.030
*Statistically significant (at the 95% level) associations are identified by bold type.            
